

IN THE NAME OF GOD



STROKE RISK FACTORS AND TREATMENT



**DR.Leila Poorsaadat Assistant Professor Of
Neurology,AUMS**

WHAT IS A STROKE?

A STROKE IS A MEDICAL EMERGENCY!


A STROKE OCCURS WHEN THE BLOOD FLOW TO A PART OF THE BRAIN IS INTERRUPTED

LACK OF BLOOD SUPPLY MEANS THAT NOT ENOUGH OXYGEN OR NUTRIENTS REACH THE BRAIN AND THE BRAIN CELLS BECOME DAMAGED OR PERMANENTLY DESTROYED
DEPENDING ON WHICH PART OF THE BRAIN IS AFFECTED, DIFFERENT SYMPTOMS CAN OCCUR

IF NOT TREATED IN TIME, A STROKE CAN HAVE EMOTIONAL, PHYSICAL OR EVEN FATAL CONSEQUENCES



STROKE TYPES AND INCIDENCE



Stroke is a Major Public Health Problem

STROKE CAN AFFECT ANYONE AT ANY TIME

6
MILLION
N
WORLDWIDE,
NEARLY
6 MILLION
PEOPLE **DIE**
EACH **YEAR**
FROM A
STROKE^{1,2}

1 IN 4
WORLDWIDE, 1
IN 4 PEOPLE ON
AVERAGE WILL
SUFFER A
STROKE IN
THEIR
LIFETIME
1

EVERY 6
SECOND
S
EVERY 6
SECONDS,
SOMEONE
DIES FROM
A STROKE^{1,2}

1. World Stroke Organization Campaign. <http://www.world-stroke.org/advocacy/world-stroke-campaign>

2. MacKay J, Mensah G. WHO, 2004. http://www.who.int/cardiovascular_diseases/resources/atlas/en/#

HOW DO I KNOW IF SOMEONE IS HAVING A STROKE?

BE SUSPICIOUS OF A STROKE IF ANY OF THE FOLLOWING SYMPTOMS OCCUR

SEVERE,
SUDDEN-
ONSET
HEADACHE

DIZZINESS

UNCONSCIOUSNESS

DIFFICULTY
TALKING,
FORMING
WORDS OR
SLURRING
WORDS

CONFUSION
AND/OR
PROBLEMS
UNDERSTAN-
DING WHAT
IS BEING
SAID

DROOPING
OF THE
MOUTH
ON ONE
SIDE

WEAKNESS
OR COMPLETE
LOSS OF MOVEMENT
AND/OR SENSATION
IN ONE OR MORE
LIMBS

VISUAL
DISTURBAN-
CE OR LOSS
OF SIGHT IN
ONE OR
BOTH EYES



RISK FACTORS

Modifiable


- ◆ Hypertension
- ◆ Diabetes mellitus
- ◆ Atrial fibrillation
- ◆ Dyslipidemia
- ◆ Smoking tobacco
- ◆ Sedentary lifestyle
- ◆ Kidney disease
- ◆ Sleep apnea
- ◆ Heavy alcohol intake
- ◆ Diet

Nonmodifiable

- ◆ Male sex
- ◆ Genetic susceptibility
- ◆ Age



AGE AND SEX IN STROKE



HTN

Hypertension is now defined by a blood pressure $>130/80$ mm Hg. Multiple studies have demonstrated a benefit to reducing blood pressure to $<140/85$ mm Hg.

A more aggressive goal of a systolic blood pressure <130 mm Hg in patients with small vessel stroke was shown to reduce hemorrhagic stroke risk by 63% but did not significantly reduce ischemic stroke risk.

However, in patients who have diabetes mellitus, an aggressive blood pressure reduction to a systolic blood pressure <120 mm Hg reduced the risk of any stroke by 41%.

Patients with hypertension should be treated with lifestyle and medical therapy to achieve a blood pressure $<130/80$ mm Hg.



Diabetes Mellitus

Diabetes mellitus is an independent risk factor for stroke

It conveys greater risk in patients younger than 65 years of age and in women.

Duration of diabetes mellitus of more than 3 years increases the risk of stroke by **74%.**

A glycated hemoglobin goal of less than 7% has been recommended to prevent microvascular complications of type II diabetes.



Atrial Fibrillation

Atrial fibrillation is an important mechanism of stroke, particularly in the Elderly.

The prevalence of atrial fibrillation increases with age, and women are at a higher risk of having a stroke due to atrial fibrillation

Both paroxysmal and permanent atrial fibrillation convey risk

Oral anticoagulant therapy with a direct oral anticoagulant (dabigatran, rivaroxaban, apixaban, edoxaban) or warfarin can significantly reduce the risk of stroke.



The risk of stroke in atrial fibrillation can be assessed by using the **CHA₂DS₂VASc** (**congestive heart failure, hypertension, age 75 years or older, diabetes mellitus, stroke, vascular disease, age 65 to 74 years, sex category [female sex]**) score

Anticoagulation is recommended for patients with a **CHADS₂-VASc** score of 1 or greater unless the score is solely based on female sex, in which case another risk factor is required



Dyslipidemia

Although high levels of cholesterol and low-density lipoprotein predispose to ischemic stroke (especially of atherosclerotic mechanism), low levels have been associated with an increased risk of intracerebral hemorrhage.

Although some studies report an association between either low high-density lipoprotein or high triglycerides and stroke, others have found no association.

Diet and lifestyle changes are the first step in reducing stroke risk.



Smoking

Active smoking increases the risk of stroke 2 to 4 times.

Smoking cessation is effective in reducing risk and can be achieved through counseling in combination with medications (nicotine replacement, bupropion, varenicline)

Passive exposure to secondhand smoke also increases stroke risk by 25%



Sedentary Lifestyle

Physical inactivity is a risk factor for stroke.

Several trials have demonstrated the protective effect of physical activity.

Moderate to vigorous–intensity aerobic exercise for at least 30 minutes a day, 3 to 4 times a week is recommended



Kidney Disease

Several studies have identified kidney disease as a risk factor for stroke.

The risk of stroke is 5 to 30 times higher in patients with chronic kidney disease, especially in patients on dialysis.

Blood pressure control is particularly important to prevent stroke in this population.



Sleep Apnea

Sleep apnea is a common condition and has been associated with stroke.

the Epworth Sleepiness Scale or Berlin Questionnaire, can be used to screen patients who may be considered for polysomnography



Alcohol Intake

The association between alcohol consumption and ischemic stroke is described as J-shaped in that the risk of stroke is higher with abstinence versus low intake (1 drink per day for women, ≤ 2 drinks per day for men).

There is also a relationship between heavy alcohol use and intracerebral hemorrhage.

Patients who do not drink alcohol should not be encouraged to start.

People who drink heavily should be advised to limit their intake



Diet

A diet rich in fruits and vegetables may be beneficial in reducing risk of stroke.

In addition, **the Dietary Approaches to Stop Hypertension (DASH) and Mediterranean diets appear to provide a protective effect emphasize fruits, vegetables, fish, legumes, and white meat and are low in sodium and high in potassium**



CONCLUSION

Up to 90% of all first strokes can be prevented with risk factor modification.

This emphasizes the importance of reinforcing healthy lifestyle choices in childhood and screening for modifiable risk factors in young and middle-aged adults





Time lost is Brain lost



FACE ARM SPEECH TEST (F.A.S.T.)

TO CHECK FOR STROKE SYMPTOMS, REMEMBER
F.A.S.T.

FACE



**FACE
DROOPING**
or asymmetry
on smiling

ARMS



**ARM
WEAKNESS**
or paralysis on
one side

SPEECH



**SPEECH
DIFFICULTY**
or slurring of
speech

TIME



TIME TO CALL
the emergency
services*



ACTILYSE:

IT IS A RECOMBINANT DNA-DERIVED VERSION OF A NATURALLY OCCURRING TISSUE PLASMINOGEN ACTIVATOR PROTEIN NORMALLY SECRETED BY HUMAN ENDOTHELIAL CELLS.


PURIFIED GLYCOPROTEIN WITH
527 AMINO ACIDS

CONVERTS PLASMINOGEN
IN THE PRESENCE OF
FIBRIN TO PLASMIN

SHORT HALF-LIFE <5MIN

CLEARED BY THE LIVER

Fibrinolysis



ACTILYSE:

ACTILYSE IS SUPPLIED IN VIALS AS A DRY POWDER AND SOLVENT FOR INJECTION AND INFUSION.

THE RECONSTITUTED SOLUTION
CONTAINS
1 MG ALTEPLASE/1 ML.

1 VIAL WITH 467 MG POWDER
CONTAINS:

10 MG ALTEPLASE, OR

1 VIAL WITH 933 MG POWDER
CONTAINS:


20 MG ALTEPLASE, OR

**1 VIAL WITH 2333 MG POWDER
CONTAINS:
50 MG ALTEPLASE.**




FEW IMPORTANT CHANGES UPDATED GUIDELINES

PATIENTS ELIGIBLE FOR INTRAVENOUS rt-PA SHOULD RECEIVE INTRAVENOUS rt-PA EVEN IF ENDOVASCULAR TREATMENTS ARE BEING CONSIDERED (CLASS I; LEVEL OF EVIDENCE A).



IF ENDOVASCULAR THERAPY IS CONTEMPLATED, A NON-INVASIVE INTRACRANIAL VASCULAR STUDY IS STRONGLY RECOMMENDED DURING THE INITIAL IMAGING EVALUATION OF THE ACUTE STROKE PATIENT BUT SHOULD NOT DELAY INTRAVENOUS rt-PA IF INDICATED.

THE BENEFITS OF ADDITIONAL IMAGING BEYOND CT AND CTA OR MR AND MRA, SUCH AS CT PERFUSION OR DIFFUSION- AND PERFUSION-WEIGHTED IMAGING, FOR SELECTING PATIENTS FOR ENDOVASCULAR THERAPY ARE UNKNOWN (*CLASS IIB; LEVEL OF EVIDENCE C*).




STEP 1:
Plain CT



STEP 2:
rt-PA



STEP 3:
CT Angio



STEP 4:
Endovascular



Indications

Diagnosis of ischemic stroke with disabling neurologic deficit (regardless of severity)	Same
Symptom onset ^b within 4.5 hours	Within 3 hours
Wake-up stroke with diffusion-weighted imaging-FLAIR mismatch on MRI ^c	Not mentioned
Age ≥ 18 years	Warning for age >77 years with risk factors for intracranial hemorrhage

Contraindications^d

Severe head trauma within 3 months	Contraindicated
Ischemic stroke within 3 months	Removed ^e
Previous intracranial hemorrhage	Warning for recent intracranial hemorrhage (contraindicated if active intracranial hemorrhage)
Suspected subarachnoid hemorrhage	Contraindicated
Suspected infective endocarditis	Not listed
Suspected aortic arch dissection	Not listed
Recent intracranial or intraspinal surgery (within 3 months)	Contraindicated
Intracranial intraaxial neoplasm	Not listed
Gastrointestinal malignancy or gastrointestinal bleeding within previous 21 days	Warning



American Heart Association Guideline 2019¹**US Food and Drug Administration (FDA) Package Insert 2015¹⁴****Contraindications^d**

Active internal bleeding

Contraindicated

Systolic blood pressure (BP) >185 mm Hg or diastolic BP >110 mm Hg that cannot be lowered safely

Contraindicated for severe uncontrolled hypertension (BP values removed^e); warning for BP >175/110 mm Hg

Bleeding diathesis

Contraindicated for bleeding diathesis (laboratory values removed^e)

International normalized ratio (INR) >1.7

Heparin within 48 hours with abnormal activated partial thromboplastin time

Low-molecular-weight heparin full treatment dose within previous 24 hours

Platelets <100,000/mm³

Current use of direct thrombin inhibitor or factor Xa inhibitor with abnormal coagulation tests^f

CT showing acute hemorrhage

Contraindicated

CT showing extensive hypodensity (eg, >1/3 of the cerebral hemisphere)

Removed^e



SECONDARY PREVENTATION

	Acute Phase (hours to days)	Chronic Phase (months to years)
Aspirin monotherapy	Aspirin 160-325 mg daily	Aspirin 81 mg daily
Clopidogrel monotherapy	Not specifically evaluated	Clopidogrel 75 mg daily
Aspirin and clopidogrel combination therapy	For minor stroke or transient ischemic attack; clopidogrel 300-600 mg load, followed by 75 mg daily for 21 days and then aspirin or clopidogrel monotherapy; reasonable to start within 24-72 hours of symptom onset	Not recommended
Extended-release dipyridamole and aspirin	Not recommended	Extended-release dipyridamole 200 mg plus aspirin 25 mg 2 times a day



ABCD2 SCORE FOR RISK OF RECURRENT STROKE AFTER TRANSIENT ISCHEMIC ATTACK

Clinical Characteristic	Points
Age of 60 years or older	
No	+0
Yes	+1
Blood pressure $\geq 140/90$ mm Hg	
No	+0
Yes	+1
Clinical features	
Unilateral weakness	+2
Speech disturbance without weakness	+1
Other symptoms	+0
Duration of symptoms	
<10 minutes	+0
10–59 minutes	+1
≥ 60 minutes	+2
Diabetes mellitus	
No	+0
Yes	+1



Predicted Risk of Recurrent Stroke After Transient Ischemic Attack^a

ABCD ² Score	Risk Category	Stroke Risk (%)		
		2-day	7-day	90-day
0-3	Low	1.0	1.2	3.1
4-5	Moderate	4.2	5.9	9.8
6-7	High	8.1	11.7	17.8



ANTI COAGULANT THERAPY

- The cardioembolic
- indications that typically justify anticoagulation include nonvalvular atrial
- fibrillation (discussed in detail below), known left atrial or left ventricular
- thrombus, acute anterior ST-segment elevation myocardial infarction with
- anterior apical akinesis or dyskinesis, mechanical left ventricular assist device,
- left ventricular ejection fraction less than 35%, and valvular heart disease
- including rheumatic mitral valve disease or mechanical prosthetic heart valves
- in the aortic or mitral position.



NOAC

- Direct oral anticoagulants have fixed dosing without the need for frequent monitoring, as well as fewer drug-drug interactions and a more rapid and predictable onset of action than warfarin



Property	Warfarin	Rivaroxaban	Dabigatran	Apixaban	Edoxaban
Mechanism	Vitamin K antagonist	Factor Xa inhibitor	Direct thrombin inhibitor	Factor Xa inhibitor	Factor Xa inhibitor
Typical dose for atrial fibrillation	Variable	20 mg daily	150 mg 2 times a day	5 mg 2 times a day	60 mg daily
Renal dose adjustment	No	Yes	Yes	Yes	Yes
Half-life	20-60 hours	5-9 hours	12-17 hours	~12 hours	8-10 hours
Onset of action	24-72 hours	3-4 hours	0.5-2 hours	3-4 hours	1-2 hours



Blood Pressure Categories




BLOOD PRESSURE CATEGORY	SYSTOLIC mm Hg (upper number)		DIASTOLIC mm Hg (lower number)
NORMAL	LESS THAN 120	and	LESS THAN 80
ELEVATED	120 - 129	and	LESS THAN 80
HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 1	130 - 139	or	80 - 89
HIGH BLOOD PRESSURE (HYPERTENSION) STAGE 2	140 OR HIGHER	or	90 OR HIGHER




- Hypertension is an important target for secondary stroke prevention
- combination of an angiotensin-converting enzyme inhibitor and a diuretic, other Acute antihypertensive therapy is typically indicated when blood pressure is $>220/120$ mm Hg
- but more stringent goals can be justified when other conditions such as end organ damage, aortic dissection, or preeclampsia/ eclampsia are apparent.
- For patients who have received intravenous (IV) thrombolytic therapy, blood pressure should be maintained $<180/105$ mmHg for the first 24 hours.
- For patients with acute stroke, waiting 24 to 72 hours to initiate or reintroduce an antihypertensive regimen is reasonable, and for those



Core drug-treatment strategy for uncomplicated hypertension



2013 ACC/AHA Guidelines: 4 Major Statin Benefit Groups



*Clinical ASCVD is defined as acute coronary syndrome, history of MI, stable/unstable angina, coronary or other revascularization, stroke, TIA, or PAD.

EUROPEAN TREATMENT GOAL FOR LDL-C ACROSS CATEGORIES OF TOTAL CVD RISK

LDL-C goal + $\geq 50\%$ reduction from baseline


116 mg/dL
(3.0 mmol/L)

100 mg/dL
(2.6 mmol/L)

70 mg/dL
(1.8 mmol/L)

55 mg/dL
(1.4 mmol/L)

40 mg/dL
(1.0 mmol/L)



THANK YOU

